This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,
GE HealthCare has signed an agreement with Axim Life Isotopes South Africa (Pty) Ltd. GE HealthCare will deliver the Cyclotrons to ALISA’s laboratory facility in Midrand, South Africa early next year, giving patients in Africa access to medical advancements.
tesla MRI AI body composition analysis Cardiac PET Cryo/thermoablation CT colonography Genicular artery embolization Hyperpolarized xenon-129 MRI PET/MRI Photon-counting CT Radiomics Theranostics Whole-body MRI screening Image of the Year 3D PET/MR image. PETscans predict patient response to Pluvicto.
Alzheimer’s has been a formidable challenge for our society, patients, caregivers, and healthcare systems for decades. Additionally, an increasing aging population has further exacerbated the burden of this disease on healthcare systems. Beyond coverage, improved payment policies can help increase access to PETscans as well.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content